The study cohort included some 1,400 alcohol-dependent individuals, more than half of whom also smoked. At the end of the 16-week trial, alcohol-dependent subjects who smoked and who received naltrexone had better outcomes than alcohol-dependent subjects who smoked and who received a placebo. Alcohol-dependent, nonsmoking subjects who received naltrexone did not have better outcomes than alcohol-dependent, nonsmoking subjects who got a placebo.
In yet another study, the addition of gabapentin to naltrexone improved drinking outcomes over naltrexone alone in 150 alcohol-dependent subjects. For more information about this study, see Psychiatric News .